Jay Hou

Jay Hou

Auto-generated profile, based on publicly available information

Jay Hou

Department of Neurosurgery, Rhode Island Hospital—Brown University Health, Providence, Rhode Island

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Nature Materials
Verified
Journal Article
Closed access
PDF file
AIAleksi Isomursu
Aleksi Isomursu
KPKeun-Young Park
Keun-Young Park
JHJay Hou
Jay Hou
BCBo Cheng
Bo Cheng
MMMathilde Mathieu
Mathilde Mathieu
DODavid J. Odde
David J. Odde

27 October 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
AIAleksi Isomursu
Aleksi Isomursu
KPKeun-Young Park
Keun-Young Park
JHJay Hou
Jay Hou
BCBo Cheng
Bo Cheng
GSGhaidan Shamsan
Ghaidan Shamsan
DODavid J. Odde
David J. Odde
Durotaxis – the ability of cells to sense and migrate along stiffness gradients – is important for embryonic development and has been implicated in pathologies including fibrosis and cancer. Although cellular processes can sometimes turn toward softer environments, durotaxis at the level of cells has thus far been observed exclusively as migration from soft to stiff regions. The molecular basis of durotaxis, especially the factors that contribute to different durotactic behaviors in various cell types, are still inadequately understood. With the recent discovery of ‘optimal stiffness’, where cells generate maximal traction forces on substrates in an intermediate stiffness range, we hypothesized that some migratory cells may be capable of moving away from stiff environments and toward matrix on which they can generate more traction. Combining hydrogel-based stiffness gradients, live-cell imaging, genetic manipulations, and computational modeling, we found that cells move preferentially toward their stiffness optimum for maximal force transmission. Importantly, we directly observed biased migration toward softer environments, i.e. ‘negative durotaxis’, in human glioblastoma cells. This directional migration did not coincide with changes in FAK, ERK or YAP signaling, or with altered actomyosin contractility. Instead, integrin-mediated adhesion and motor-clutch dynamics alone are sufficient to generate asymmetric traction to drive both positive and negative durotaxis. We verified this mechanistically by applying a motor-clutch-based model to explain negative durotaxis in the glioblastoma cells and in neurites, and experimentally by switching breast cancer cells from positive to negative durotaxis via talin downregulation. Our results identify the likely molecular mechanisms of durotaxis, with a cell’s contractile and adhesive machinery dictating its capacity to exert traction on mechanically distinct substrates, directing cell migration.

1 January 2024 in Neuro-Oncology Advances
Verified
Journal Article
Open access
PDF file
JHJay Hou
Jay Hou
MMMariah McMahon
Mariah McMahon
TJTyler Jubenville
Tyler Jubenville
JSJann N Sarkaria
Jann N Sarkaria
CCClark C Chen
Clark C Chen
DODavid J Odde
David J Odde
Background: Glioblastoma is the most aggressive malignant brain tumor with poor survival due to its invasive nature driven by cell migration, with unclear linkage to transcriptomic information. The aim of this study was to develop a physics-based framework connecting to transcriptomics to predict patient-specific glioblastoma cell migration. Methods and Results: We applied a physics-based motor-clutch model, a cell migration simulator (CMS), to parameterize the migration of glioblastoma cells and define physical biomarkers on a patient-by-patient basis. We reduced the 11-dimensional parameter space of the CMS into 3 principal physical parameters that govern cell migration: motor number—describing myosin II activity, clutch number—describing adhesion level, and F-actin polymerization rate. Experimentally, we found that glioblastoma patient-derived (xenograft) cell lines across mesenchymal (MES), proneural, and classical subtypes and 2 institutions (N = 13 patients) had optimal motility and traction force on stiffnesses around 9.3 kPa, with otherwise heterogeneous and uncorrelated motility, traction, and F-actin flow. By contrast, with the CMS parameterization, we found that glioblastoma cells consistently had balanced motor/clutch ratios to enable effective migration and that MES cells had higher actin polymerization rates resulting in higher motility. The CMS also predicted differential sensitivity to cytoskeletal drugs between patients. Finally, we identified 18 genes that correlated with the physical parameters, suggesting transcriptomic data alone could potentially predict the mechanics and speed of glioblastoma cell migration. Conclusions: We describe a general physics-based framework for parameterizing individual glioblastoma patients and connecting to clinical transcriptomic data that can potentially be used to develop patient-specific anti-migratory therapeutic strategies.

24 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JHJay J Hou
Jay J Hou
MMMariah McMahon
Mariah McMahon
JSJann N. Sarkaria
Jann N. Sarkaria
CCClark C. Chen
Clark C. Chen
DODavid J. Odde
David J. Odde
Glioblastoma is the most aggressive malignant brain tumor with poor survival due to its invasive nature driven by cell migration, with unclear linkage to transcriptomic information. Here, we applied a physics-based motor-clutch model, a cell migration simulator (CMS), to parameterize the migration of glioblastoma cells and define physical biomarkers on a patient-by-patient basis. We reduced the 11-dimensional parameter space of the CMS into 3D to identify three principal physical parameters that govern cell migration: motor number – describing myosin II activity, clutch number – describing adhesion level, and F-actin polymerization rate. Experimentally, we found that glioblastoma patient-derived (xenograft) (PD(X)) cell lines across mesenchymal (MES), proneural (PN), classical (CL) subtypes and two institutions (N=13 patients) had optimal motility and traction force on stiffnesses around 9.3kPa, with otherwise heterogeneous and uncorrelated motility, traction, and F-actin flow. By contrast, with the CMS parameterization, we found glioblastoma cells consistently had balanced motor/clutch ratios to enable effective migration, and that MES cells had higher actin polymerization rates resulting in higher motility. The CMS also predicted differential sensitivity to cytoskeletal drugs between patients. Finally, we identified 11 genes that correlated with the physical parameters, suggesting that transcriptomic data alone could potentially predict the mechanics and speed of glioblastoma cell migration. Overall, we describe a general physics-based framework for parameterizing individual glioblastoma patients and connecting to clinical transcriptomic data, that can potentially be used to develop patient-specific anti-migratory therapeutic strategies generally. Significance Statement: Successful precision medicine requires biomarkers to define patient states and identify personalized treatments. While biomarkers are generally based on expression levels of protein and/or RNA, we ultimately seek to alter fundamental cell behaviors such as cell migration, which drives tumor invasion and metastasis. Our study defines a new approach for using biophysics-based models to define mechanical biomarkers that can be used to identify patient-specific anti-migratory therapeutic strategies.

1 January 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
JHJay Hou
Jay Hou
MKMarcus D. Kelly
Marcus D. Kelly
WGWendy R. Gordon
Wendy R. Gordon
DODavid J. Odde
David J. Odde
Collagen is the most abundant fibrous protein component in the human extracellular matrix (ECM), with essential functions of enabling cell adhesion and migration. As animal cells apply traction forces to the ECM, they deform ECM structures and alter their mechanical properties, while also using these forces to generate cell movement. Therefore, it is crucial to understand how cells apply traction forces onto collagen matrices. While the methodology for 2D traction force measurement on homogeneous elastic materials is well-established, the approach for 3D traction forces is still in its early stages. In this review, we will discuss the basic theory and methods in typical 2D and 3D traction force microscopy (TFM) to determine cell traction forces on 2D and 3D substrates, the measurements of collagen gel mechanics, measurements of cell traction forces within collagen gels, and molecular tension sensors to estimate cell traction force at the molecular level.